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Here we report on a case of Philadelphia chromosome positive B lymphoblastic leukemia (Ph+ALL), which
developed following a long duration of essential thrombocythemia (ET). A mutational analysis of Janus Kinase 2
(JAK2) revealed that the V617F mutation was present in granulocytes and in hematopoietic stem and progenitor
cells (HSPCs), but not in the CD34+CD19+ population that mostly consists of Ph+ALL cells, indicating that this
Ph+ALL clone did not originate from the ET clone carrying the JAK2-V617F mutation. The minor BCR-ABL1 fusion
was detected not only in the CD34+CD19+ population but also in HSPCs and granulocytes, indicating that the
Philadelphia chromosome was acquired in an early hematopoietic stage at least prior to the commitment to B cell
development. Upon dasatinib treatment, the minor BCR-ABL1 transcript rapidly disappeared in HSPCs but persisted
in the CD34+CD19+ population. A relapse of Ph+ALL occurred nine months later without the disappearance of the
minor BCR-ABL1 transcript in the bone marrow cells during the treatment course, suggesting that a resistant Ph+ALL
clone may have arisen or been selected in the committed B cells rather than in HSPCs. This case report may partly
contribute to filling the gap between previous data acquired from mice experiments and the phenomenon in real
patients.
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Resistant cloneBackground
Myeloproliferative neoplasms (MPNs) are a group of stem
cell disorders including polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF),
all of which are characterized by the overproduction of
mature blood cells. It is well known that patients with
MPNs often develop acute myeloid leukemia (AML) [1],
but also it has been occasionally reported that MPNs may
be associated with lymphoid malignancies including non-
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unless otherwise stated.and multiple myeloma [2,3]. However, a genetic associ-
ation between B lymphoblastic leukemia (B-ALL) and
MPNs is rarely observed [4,5].
The JAK2-V617F mutation is one of the major causes
of MPNs and is present in the vast majority of these pa-
tients (90–95% of PV patients and 50–60% of ET and
PMF patients) [6]. Intriguingly, transformation of the
JAK2-V617F positive clones to AML is observed mainly
in cases of primary or secondary myelofibrosis while
AML clones arising directly from PV and ET are mostly
JAK2 wild-type, indicating clonal heterogeneity of MPNs
[1]. Similarly, in cases of CLL or diffuse large B cell
lymphoma following MPNs, the JAK2-V617F mutation
is detected either in both MPN cells and B lymphoidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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other residues, such as R683, are also observed in high-
risk childhood acute lymphoblastic leukemia [7], sup-
porting the theory that JAK2 mutations may confer a
growth advantage on B lymphocytes.
The BCR-ABL1 fusion kinase encoded by the Philadelphia
(Ph) chromosome, which arises from the chromosomal
translocation t(9;22), is a major cause of chronic myeloid
leukemia (CML) as well as of Ph+ acute lymphoblastic
leukemia (Ph+ALL). CML is presumed to arise from
aberrant Ph+ stem cells which are enriched in the
CD34+CD38- hematopoietic stem cell population. Tyro-
sine kinase inhibitors (TKIs) such as imatinib and dasati-
nib that specifically target the BCR-ABL1 kinase have
improved the outcomes of patients with CML but have
failed to provide a cure for the disease. The maintenance
of leukemia stem cells (LSCs), which are capable of en-
graftment in immunodeficient mice, does not require the
BCR-ABL1 kinase activity [8], and hence the disease usu-
ally relapses once TKI treatment is discontinued [9].
Ph+ALL is a subtype of B-ALL with a particularly poor
prognosis even in the current era of TKIs. It remains un-
clear whether Ph+ALL arises from the CD34+CD19- popu-
lation before the commitment to B cell development [10]
or from the CD34+CD19+ pro-B population [11]. LSCs of
B-ALL do not appear to be enriched in a specific popula-
tion in xenotransplanted mice [12,13] but it is unclear
whether a specific population resistant to TKIs, as in the
case of CML-LSCs, exists in Ph+ALL patients.
In this case report, we describe a particular case of Ph+ALL
that followed ET, examine which cell population is the tar-
get for two major genetic alterations, JAK2-V617F and
minor BCR-ABL1 to understand the clonal architecture
between Ph+ALL and ET, and investigate whether the sen-
sitivity of subpopulations of Ph+ALL to dasatinib differs.
Case presentation
In 1995, a 51-year-old woman was diagnosed as ET with
the clinical examinations revealing a platelet count of
1240 × 109 /L, total white blood cell count of 7.9 ×
109 /L, hemoglobin levels of 12.1 g/dl, and a marked
proliferation of large, mature megakaryocytes in the
bone marrow aspirate. She had been treated with only
an anti-thrombotic agent for more than ten years except
for one year with a cytoreductive therapy utilizing hy-
droxyurea that was discontinued in 2003 due to intoler-
ance, and her disease had been well controlled without
any thrombotic events or any signs of progression to ter-
minal myelofibrosis. In October 2011, at the age of 67,
the platelet count suddenly decreased to 336 × 109 /L
and blasts were detected with a total leukocyte count of
8.9 × 109 /L (14% blasts) in the peripheral blood. Com-
puted tomography (CT) scans of the abdomen and pelvis
showed no splenomegaly. A bone marrow examinationrevealed hypercellularity with increased numbers of
megakaryocytes and leukemic blasts, accounting for 76%
of the total nucleated cells. Fluorescence-activated cell
sorting (FACS) analysis showed a B-ALL phenotype
(CD34+ CD19+ CD10+ CD13+ HLA-DR+) and Southern
blot analysis clearly demonstrated monoclonality with
a rearrangement of the immunoglobulin heavy chain
gene. Cytogenetic analysis as well as Fluorescence in situ
hybridization (FISH) analysis revealed clonal abnormalities
with translocation t(9;22)(q34; q11.2) of the Ph chromo-
some and monosomy 7. The presence of the minor BCR-
ABL1 fusion transcript was confirmed using a reverse
transcription–polymerase chain reaction (RT-PCR) and
direct Sanger sequencing. Based on these results, we diag-
nosed Ph+ALL that may have transformed from ET.
Subsequently, after acquiring a written informed con-
sent, we investigated the JAK2-V617F mutational status
in peripheral granulocytes isolated by Percoll density
gradient centrifugation and in FACS-sorted lineage-
CD34+ HSPCs and CD34+CD19+ B-ALL cells from per-
ipheral blood mononuclear cells (PBMCs) at diagnosis.
The sequencing analysis performed as previously de-
scribed [14] showed that the JAK2-V617F mutation was
present clearly in granulocytes and to a lesser extent in
HSPCs, but not at all in B-ALL cells (Figure 1A). These
results indicate that the B-ALL clone did not originate
from the ET clone with the JAK2-V617F mutation.
Next in order to determine the stage in which the Ph
chromosome was initially acquired, we separated CD34+
cells into four populations according to CD10 and CD19
expression (Figure 1B) after the exclusion of populations
with lineage markers other than B cell markers including
CD10, CD19, and CD20, and then performed the RT-
PCR for the minor BCR-ABL1 transcript. As expected,
the amplification of the transcript was observed in
the CD34+CD19+CD10+ and the CD34+CD19+CD10-
populations both of which are committed to B cell de-
velopment. However, the CD34+CD19-CD10- population
which enriches HSPCs also expressed the minor BCR-
ABL1 transcript (Figure 1C). FISH analysis revealed that
54% of CD34+CD19-CD10- cells as well as 10% of granu-
locytes that are defined as segmented nuclear cells car-
ried the Ph chromosome (Figure 1D). Taken together,
these findings suggest that the Ph chromosome was ac-
quired during an early hematopoietic stage before the
commitment to B cell development.
After the diagnosis, the patient was treated with dasa-
tinib and prednisolone. Four weeks later, we observed a
great reduction of leukemia cells. To investigate whether
the most primitive population in Ph+ALL were less sen-
sitive to TKIs as in the case of CML, we separated bone
marrow mononuclear cells (BMMCs) into three popula-
tions according to the expression level of CD34 and
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Figure 1 Analysis of the molecular based clonal architecture. (A) Sequencing of JAK2. Granulocytes and FACS-sorted lineage-CD34+ cells
(HSPCs) and CD34+CD19+ B-ALL cells were analyzed. The JAK2-V617F mutation was not detected in B-ALL cells. Asterisk indicates nucleotide 1849
of JAK2. Lineage markers included CD2, CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, CD56 and CD235. (B) FACS analysis and sorting of
PBMCs at diagnosis. The gating strategy to isolate four populations is shown. Lineage markers included CD2, CD3, CD4, CD7, CD8, CD11b, CD14,
CD56 and CD235. (C) RT-PCR analysis for each population (gated in (B)). Plasmids containing the amplified region of minor BCR-ABL or GAPDH
were used as positive controls (PC). Distilled water was used as the negative control (NC). The left lane shows the size marker. The Minor BCR-ABL
transcript was also detected in CD34+CD19-CD10- cells. (D) FISH analysis of BCR-ABL utilizing probes of Vysis LSI ASS-ABL for 9q34 (red) and Vysis
LSI BCR for 22q11.2 (green). One red-green fusion signal specified by the arrow* indicates the presence of BCR-ABL. One smaller red signal
specified by the arrow** indicates the remaining part of 9q34. Translocation t(9;22) was detected in both CD34+CD19-CD10- cells at diagnosis
and in segmented nuclear cells four days after the initiation of dasatinib treatment.
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BCR-ABL1 transcript was no longer detected in the
CD34+CD19- population that was almost negative for
CD10 corresponding to the CD34+CD19-CD10- popula-
tion depicted in Figure 1B-D, which carried the minor
BCR-ABL1 transcript at diagnosis. However, the tran-
script was still detected in the CD34+CD19+ population
(Figure 2B). Ten weeks later, the patient achieved cyto-
genetic remission with an increase in the platelet count,
suggesting that the ET clone had repopulated during
treatment. However, the minor BCR-ABL1 transcript
was still detected at low levels in the bulk bone marrow
cells (Figure 2B), and finally the Ph+ALL relapsed withthe T315I mutation nine months later, indicating that a
resistant clone may not always derive from the most
primitive population such as HSPCs.
Conclusions
Cases of ET and B-ALL comorbidity are very rare. We
initially thought this case was a transformation of ET to
B-ALL similar to lymphoid crisis of CML, but were
proven wrong when the mutational analysis of JAK2
clearly showed that the B-ALL clone did not originate
from the ET clone with the JAK2-V617F mutation.
These results raise two hypotheses. One is that a micro-






















Figure 2 Chase of the minor BCR-ABL1 positive clone during clinical course. (A) FACS analysis and sorting of BMMCs at four weeks after
the initiation of dasatinib treatment. The gating strategy to isolate three populations is shown. Lineage markers include CD2, CD3, CD4, CD7,
CD8, CD11b, CD14, CD56 and CD235. (B) RT-PCR analysis for each population (gated in (A)) at four weeks and bulk BMMCs at ten weeks. Minor
BCR-ABL transcripts was clearly detected only in CD34+CD19+ cells but not in CD34+CD19- at four weeks and still detected in bulk BMMCs in low
levels at ten weeks. Positive control (PC), plasmids containing the amplified region of minor BCR-ABL or the GAPDH gene; negative control (NC),
distilled water.
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MPNs can remodel the bone marrow niche may support
this hypothesis [15]. The other is that an aberrant clone
may develop independently to ET or B-ALL with the
additional hit of the JAK2-V617F mutation or the trans-
location t(9;22) respectively. A previous report that del
(11q) was detected both in a JAK2-V617F positive MPN
clone and in a JAK2-V617F negative AML clone in the
same patient may support this hypothesis [16]. However,
Monosomy 7 which was positive at diagnosis of Ph+ALL
was not detected in bone marrow cells in cytogenetic
remission after dasatinib treatment, indicating it was
probably a second hit after the translocation t(9;22) in
Ph+ALL cells. Since mutations in epigenetic regulators
are common in MPNs [17], we also performed the mu-
tational analysis for several genes such as the terminal
exon of DNMT3A including R882, exon 4 of IDH1 in-
cluding R132, exon 4 of IDH2 including R140 and R172,
and exon 3 to 11 of TET2, but failed to find any founder
mutations. The recent progress of high-throughput se-
quencing may resolve this question in the future.
LSCs of CML are enriched in the CD34+CD38- hema-
topoietic stem cell population while those of B-ALL are
not enriched in a specific population as several reports
demonstrated that various phenotypically separated popu-lations such as HSPCs and pre-B cells possess the engraft-
ment capacity in immunodeficient mice [12,13]. Given
that LSCs of CML are resistant to TKIs due to their quies-
cence and independent maintenance from BCR-ABL kin-
ase [8], LSCs of B-ALL might be defined as a population
that is not eliminated by chemotherapy and TKI treatment
in patients. However, they have not yet been well studied
in real Ph+ALL patients treated with TKIs. The LSC-like
population of Ph+ALL in this case might exist in the
CD34+CD19+ B cell committed population rather than in
lineage-CD34+ HSPCs, since the BCR-ABL1 transcript
remained in the former but quickly disappeared in the lat-
ter at four weeks after therapy initiation, despite the latter
being more primitive. Although we could not analyze
whether the T315I mutation was acquired or selected in
this committed population due to the limited sample size,
it would be of value to examine similar cases in more de-
tail throughout the clinical courses, in order to fill the
current knowledge gap between results from mice experi-
ments and findings from real patients and to be able to
eradicate residual leukemic clones in such patients.
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